Company presentations entries
Allegria Therapeutics is a Basel-based biopharma start-up established in 2023 with a highly differentiated portfolio of therapeutic approaches to target mast cells as drivers of allergy and inflammatory disease.
Our first-in-class approaches modulate mast cell activity directly and selectively to attain a combination of better efficacy and safety as compared to approaches being pursued thus far.
May 6, 13:30 - 13:45, room Singapore
Anaveon AG is a clinical stage company developing immunotherapies for diseases with high unmet medical need.
Pipeline: ANV110: Bispecific targeting inflammation and fibrosis (Ph1); ANV200: mAb to eliminate alloreactive and autoreactive T/B cells (pre-CMC); ANV600: bispecific IL-2 agonist to activate pre-exhausted T cells (Ph1) and ANV700: IL-21-based bispecific to localize immune stimulation in the TME (pre-CMC).
Anaveon is actively Actively pursuing strategic partnerships.
May 6, 13:45 - 14:00, room Montreal
Aptar Pharma, your go-to drug delivery expert, from formulation to patient, supports pharmaceutical companies develop safe, compliant medicines for a wide range of delivery routes. Our digital healthcare solutions and investments in R&D and innovation allow us to offer proven drug delivery solutions to improve patient outcomes. Our global GMP manufacturing sites help accelerate and derisk drug development. Aptar Pharma is part of AptarGroup,Inc.(NYSE: ATR)www.aptar.com/pharma
May 6, 14:00 - 14:15, room Osaka/Samarkand
Arakena Pharmceuticals GmbH is a Basel-based biopharma start-up with a unique portfolio of potent G protein-coupled receptor kinase (GRK) inhibitors with potential for first-in-class treatment in cardiomyopathies, cardiovascular and metabolic diseases. Cardiomyopathies are responsible for heart failure, sudden cardiac death and hospitalisation due to major cardiovascular events. GRK inhibitors have demonstrated promising efficacy in a range of different heart disease models.
May 6, 14:45 - 15:00, room Singapore
Araris Biotech AG is a wholly owned subsidiary of Taiho Pharmaceutical (part of the Otsuka Holdings), pioneering a novel, best-in-class technology platform generating multi-payload antibody-drug conjugates (ADCs) in one step on native antibodies, without requiring any antibody engineering or glycan remodelling. Araris ADCs have showed excellent stability and antibody-like PK properties, leading to higher efficacy and tolerability against multiple commercially available ADCs.
May 6, 12:30 - 12:45, room Singapore
ARTBIO is a clinical-stage company developing a new class of alpha radioligand therapies (ART) using the alpha-emitting Pb212, which delivers powerful, short-lived bursts of energy into tumors for greater efficacy than other isotopes. ARTBIO's proprietary Alpha-DirectTM technology enables Pb212 production in a distributed manufacturing network that delivers its pipeline to patients. AB001 enters the clinic for prostate cancer in 2025; 3 additional programs advance quickly.
May 6, 12:45 - 13:00, room Montreal
The Life Sciences Competence Center is dedicated to fostering innovation and advancing research in the biomedical field. We are committed to developing sustainable solutions and fostering collaborations between academic and industrial partners. Our mission is to provide a valuable growth opportunity for both local and international companies operating in the industry, granting them access to cutting-edge skills, state-of-the-art technologies, and top-notch infrastructure.
May 5, 17:30 - 17:45, room Osaka/Samarkand
Atopia Therapeutics, is developing ATP-R13, a first-in-class disease-modifying oral immunotherapy targeting allergic diseases like asthma, atopic dermatitis, and food allergies. Derived from a natural bacterial protein, ATP-R13 restores immune tolerance by inducing regulatory T cells (Tregs), addressing the root cause of allergic inflammation. Atopia aims to provide curative solutions beyond symptom management and is advancing ATP-R13 toward clinical development
May 6, 13:45 - 14:00, room Singapore
Aukera is developing first-in-class mTORC1 inhibitors for the treatment of neurological disorders and cancer, focusing on areas of high unmet medical need. The preclinical lead program is a low-nanomolar protein–protein interaction inhibitor with a novel mode of action and an unmatched selectivity profile for mTORC1 over mTORC2. Aukera has developed an AI-powered drug discovery platform that leverages advanced protein design to target previously hard-to-drug proteins.
May 5, 16:00 - 16:15, room Singapore
Azafaros is a clinical-stage biotech company developing nizubaglustat, an orally available, brain-penetrant small molecule with a unique dual mode of action, targeting key pathways in GM1/GM2 gangliosidoses, Niemann-Pick type C (NPC), and other severe metabolic disorders. Following a successful Ph 2 study, Azafaros is preparing for global Ph 3 trials in GM1/GM2 gangliosidoses and NPC. In parallel, the company continues to expand its pipeline through cutting-edge research.
May 6, 14:45 - 15:00, room Montreal
Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba® for the treatment of invasive fungal infections and Zevtera® for the treatment of bacterial infections. We have preclinical and clinical anti-infective assets in our portfolio. We are located in the Basel area and listed on the SIX Swiss Exchange (SIX: BSLN).
May 5, 16:00 - 16:15, room Osaka/Samarkand
BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them.
May 5, 16:15 - 16:30, room Osaka/Samarkand
Belach Bioteknik has over 40 years of experience designing, manufacturing, and maintaining biotechnological equipment and bioprocess systems. Belach products and systems are typically tailored to individual user requirements, from lab-scale experimental bioreactors to pilot and production bioreactor systems. Belach Bioteknik serves clients in Scandinavia, Europe, and the USA. Besides distributing new equipment, Belach provides reliable yearly maintenance and service.
May 5, 14:30 - 14:45, room Osaka/Samarkand
Cellis AG is developing Macrophage Drug Conjugates (MDC). Our innovative approach is based on the groundbreaking discovery of the TRAIN mechanism unveiled by our team. Our technology works as a natural “Trojan Horse.” Our technology works as a natural “Trojan Horse.” By administering only a fraction of the drug dosage twice, we achieve a robust and durable activation of the immune system that leads to tumor regression and the development of anti-tumor resistance.
May 6, 15:45 - 16:00, room Singapore
Celonic is a “Pure Play” Mammalian Biologics CDMO. It's mission is to help its customers, primarily small to large Biotech companies, bring life-saving drugs to the market using innovative, “next generation” bioprocessing technologies such as, process intensification and full-perfusion. Celonic has a Development and Innovation Center in Basel, Switzerland (headquarters), and clinical and commercial mid-size GMP manufacturing facilities in Heidelberg, Germany.
May 5, 14:30 - 14:45, room Montreal
May 6, 12:30 - 12:45, room Montreal
CinnaGen Co. was founded in 1994 with the goal of manufacturing hi-tech products in biotechnology and related fields. Since its start of operation with 4 scientists, CinnaGen has grown to become the biggest bio-pharmaceutical manufacturer and biotech exporter in the MENA region. Our aim is to use our expertise to identify and acquire selected products through strategic partnerships to promote sustainable development in human health.
May 5, 14:45 - 15:00, room Osaka/Samarkand
Concept Life Sciences is a UK-based drug discovery CRO , helping global pharma and biotech companies accelerate their drug candidate to clinic by offering integrated drug discovery programs as well as high quality solutions in Biology, Chemistry, ADME/ DMPK, Toxicology and GMP manufacturing. Concept Life Sciences has helped pharma and biotech companies accelerate 30 candidates to preclinical stage, 21 candidates to clinic, and 4 candidates to market.
May 6, 16:15 - 16:30, room Osaka/Samarkand
Cube Biotech specializes in solving complex problems in protein research, with a specific emphasis on the challenging class of membrane proteins. We cover all stages of protein preparation utilizing our NativeMP copolymer stabilization platform, protein purification capabilities, biophysical target characterization applications, and structure determination via cryo-EM or crystallography. Cube Biotech also offers active, full-length protein targets with a native structure.
May 5, 17:15 - 17:30, room Osaka/Samarkand
Curatis Holding AG is a publicly listed company (CURN.SW) specialising in the development and commercialisation of drugs for rare and very rare diseases. Curatis has a portfolio of more than 40 marketed products and a pipeline of orphan and specialty products. More information can be found on the website www.curatis.com.
May 5, 15:45 - 16:00, room Montreal
Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™,
May 5, 16:45 - 17:00, room Osaka/Samarkand
Decisive Consulting Ltd helps pharmaceutical companies navigate market access with an “access first” approach, ensuring innovative treatments reach patients quickly. Our team of global experts brings curiosity, capability, and rebel thinking to key moments of change - supporting strategy, implementation, and insights to guide better decisions. We collaborate deeply, challenge assumptions, and empower clients to move forward with clarity and confidence.
May 6, 13:00 - 13:15, room Marriott 1+2
DeepLife is a biotech innovator using AI and single-cell omics data to accelerate drug development and provide disease-specific insights to researchers and pharmaceutical companies. By creating digital twins of cells and leveraging multi-omics data, DeepLife aims to streamline drug development and bring lab breakthroughs closer to patient care.
May 6, 13:15 - 13:30, room Osaka/Samarkand
DimericonTx is employing a novel peptidic therapeutic modality and a unique discovery engine to tackle hard-to-drug intracellular protein-protein interaction targets. Following a seed round led by AbbVie Ventures and BiomedVC in 2023, Dimericon is progressing a portfolio of preclinical programs in oncology, immunology and inflammation.
May 5, 16:15 - 16:30, room Singapore
Enamine offers end-to-end drug discovery services, from hit generation to preclinical candidate selection. With 360K+ building blocks, 4.5M+ screening compounds, and 64.9B REAL compounds, we support biotech and pharma with integrated chemistry and biology—accelerating discovery while minimizing risks and timelines.
May 6, 13:15 - 13:30, room Marriott 1+2
Encelta’s allogeneic T cells are engineered to retain full TCR function while eliminating the risk of GvHD, enabling safe, off-the-shelf use across patients. Designed to work in combination with T-cell engagers (TCEs), they restore anti-tumor immunity in patients unresponsive to TCEs alone.This off-the-shelf product offers simple logistics and outpatient accessibility, overcoming the challenges faced by the current autologous cell therapies.
May 6, 14:15 - 14:30, room Singapore
Enzene is an end-to-end CDMO with services spanning discovery, development & commercial supply, operating integrated sites in Pune (India) & New Jersey (USA). Enzene is disrupting the existing biologics manufacturing paradigm with its patented EnzeneX™ technology, which was the first fully-connected continuous manufacturing™ platform validated for commercial biologics supply. Our microbial, mammalian drug substance plants & our sterile fill & finish plant in India are EU-GMP.
May 6, 15:45 - 16:00, room Osaka/Samarkand
ExcellGene is a science-based contract research, development, and manufacturing organization. The company's services include transient gene expression, cell line generation, stable cell line development and recombinant protein manufacturing (from DNA to clinical manufacturing process). ExcellGene is a CDMO (contract development and manufacturing organization) specializing in challenging protein expression services also.
May 5, 15:00 - 15:15, room Osaka/Samarkand
We’re focused forecasting and planning experts with a mission: realizing impactful results that get your business years ahead. Join EyeOn’s speaking session at the Biotech Day in which we share practical, proven strategies to transform planning into a powerful enabler and how to apply 'Smarter Planning from Clinical to Commercial'. We’ll walk through real-life examples of integrated planning systems supporting confident decisions from development to delivery.
May 6, 12:45 - 13:00, room Marriott 1+2
FimmCyte is a Swiss biotech developing disease modifying therapies for chronic diseases through elimination of diseased cells directly. FimmCyte has a pipeline of multi-specifics with the two most advanced assets ready for IND and CMC for endometriosis and an organ fibrosis.
May 6, 12:45 - 13:00, room Singapore
FoRx Therapeutics AG develops innovative small molecule therapeutics that target DNA Damage Response (DDR) pathways for anti-cancer therapy. The company's pipeline encompasses novel, first-in-class as well as differentiated, best-in-class programs for oncology indications. The lead program is a highly potent and selective PARG inhibitor, FORX-428, which is currently in final IND-enabling studies and slated to enter the clinic in July 2025.
May 6, 13:00 - 13:15, room Montreal
Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development.
May 5, 14:45 - 15:00, room Montreal
Helbling is an internationally active and independent engineering and consulting firm employing more than 600 professionals with a focus on innovation and product development, management consulting, energy/infrastructure, mergers/acquisitions, restructuring, and real estate. We develop technologically sophisticated products for our clients, from conceptualization to industrialization, and bring innovation to life – a matter of heart, soul and actions.
May 5, 15:45 - 16:00, room Osaka/Samarkand
HemostOD is an early pre-clinical stage Swiss company producing "ex vivo", adult stem cell-derived engineered platelets, for infusion in patients suffering low platelet counts, as in thrombocytopenia and when a patient's own immune system attacks platelet transfusions from human donors.The platelets are manufactured from megakaryocyte cells and mimic the structure and biological properties of fresh human platelets, but with greatly reduced immunogenicity and purer quality.
May 6, 15:00 - 15:15, room Singapore
Immunophotonics, Inc. is a privately held biotech developing a first-in-class drug (IP-001) to reduce metastasis formation and prevent cancer recurrence in patients with solid tumors. IP-001 induces tumor-specific antitumor immune activation with sustained anticancer immune function. Safety and signs of efficacy have been demonstrated in >100 patients treated and the pivotal market access trial planned to initiate in early 2026.
May 6, 15:45 - 16:00, room Montreal
ImmunOs’ approach is based on the identification of specific human leukocyte antigen (HLA) molecules that hyper-activate the immune system of patients with severe autoimmune disorders. The company has utilized this discovery to develop an HLA-based technology platform to generate a novel class of biologic therapeutics for the treatment of cancer and autoimmune disease.
May 5, 15:15 - 15:30, room Montreal
Inthera Bioscience AG is a Swiss biotech company. Its lead compound, INTH-454, is an IND-ready oral small molecule drug binding to the Negative Elongation Factor complex of transcription (NELF). Through this binding, INTH-454 interferes with cellular checkpoints of transcription leading in turn to replicative stress induction and DNA synthesis inhibition. INTH-454 induces highly specific killing of tumor cells while leaving normal cells unharmed.
May 6, 13:00 - 13:15, room Singapore
KBI Biopharma is a global CDMO providing fully integrated, accelerated drug development and biologics manufacturing expertise. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. KBI works closely to personalize and rapidly accelerate drug development programs.
May 6, 14:45 - 15:00, room Osaka/Samarkand
Labcorp is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Learn more about us at www.labcorp.com.
May 5, 15:30 - 15:45, room Osaka/Samarkand
Legacy Healthcare is developing treatments for autoimmune diseases. Its first drug, Cinainu, demonstrated efficacy and safety in a Ph 2/3 trial in children and adolescents with Alopecia Areata. Cinainu is a first-in-class botanical drug with patent protection until 2043. Thanks to unparallel safety and efficacy, physicians say Cinainu would be their first-line treatment in a market expected to generate $5b by 2030. The company is raising funds to pursue FDA track.
May 5, 16:15 - 16:30, room Montreal
One of the world’s largest contract development & manufacturing organizations dedicated to serving the healthcare industry. Working across 5 continents, our global team of ~18,500 colleagues works alongside pharma & biotech companies to turn their breakthrough innovations into viable therapies. We support our customers globally in bringing life-saving and life-enhancing treatments to patients with a combination of cutting-edge science, smart technology and lean manufacturing.
May 6, 12:30 - 12:45, room Osaka/Samarkand
Swiss biotech company in immunology and inflammation (I&I). Our lead assets are in the allergy space, the fastest growing Type 2 immunology market with major unmet medical need.
We are currently raising our series B (USD 60M). 1/3 of the 60M series B has been already committed by current investors.
Phase 1 for our lead asset (antibody for peanut allergy) is expected to start in Q4 2025.
• 100% protection
• fewer injections/year (2 injections/year)
• rapid onset of immunity
May 5, 15:45 - 16:00, room Singapore
Menarini Biotech, a boutique, pure-play CDMO where we specialise in antibody discovery, development, and manufacture. We offer competitive pricing, fast clinical batch execution, regulatory expertise to accelerate biologics incl. enzymes, monoclonal antibodies, bi-specifics, fusion proteins, and ADCs from Research to FIH. From DNA to TOX in less then 6 months, GMP in 9 months. Those CMC services include manufacturability and scalability to ensure a seamless transition to GMP.
May 5, 17:00 - 17:15, room Osaka/Samarkand
metaLead is a spin-out from the University of Zurich pioneering innovative therapies for metal-related diseases. Our platform develops first-in-class metal-binding peptides with exceptional affinity and selectivity to desired metals. Our lead program addresses Wilson disease, a rare genetic condition causing the accumulation of toxic amounts of copper in the liver and brain. We combine cutting-edge science, drug development expertise, and patient-driven innovation.
May 6, 13:15 - 13:30, room Singapore
The patent law firm Michalski - Hüttermann & Partner is a specialized practice in the field of intellectual property law. A bias of our work lies in the field of biotechnology, and in particular the support of biotech startups, including antibodies, antibody mimetics, TCRs, ADCs, mRNA therapies, CRISPR Cas, CAR T cells and the like. We have been active in many Due Diligence projects and could support our biotech clients in deals ranging between 500 K€ and 1,2 bn €
May 6, 13:30 - 13:45, room Marriott 1+2
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of a new class of custom-built protein drugs known as DARPin therapeutics.
The Company has programs in pre-clinical and clinical development and partnerships with leading pharmaceutical companies to bring innovative solutions to cancer patients.
Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA.
May 6, 16:15 - 16:30, room Montreal
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases.
May 6, 14:15 - 14:30, room Osaka/Samarkand
MT-act is a preclinical stage company that engineered MT-discover®, a proprietary platform to deliver first-in-class drugs for uncharted enzymes, to safely restore microtubule (MT) dysfunctions in chronic diseases. Unlike classic MT drugs, our first asset MT-X01 is an optimised safe small molecule targeting a novel mode of action to improve cardiac relaxation, without impairing contractility, under development to help patients suffering from hypertrophic cardiomyopathy.
May 6, 15:15 - 15:30, room Singapore
MUVON Therapeutics is a Swiss clinical stage biotech with the goal of extending the human health span. We are developing a novel, single-use injectable tissue engineering therapy platform utilizing non-genetically modified, autologous cells for the regeneration of skeletal muscle tissue.
Our initial therapeutic focus is the treatment of stress urinary incontinence in women currently in phase II of clinical development.
May 5, 16:00 - 16:15, room Montreal
Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators — molecules that increase or decrease the activity of target receptors by binding outside of the “active site” where endogenous ligands and traditional drugs operate. Through this platform, Neurosterix’s novel drug candidates have the potential to provide me
May 6, 15:00 - 15:15, room Singapore
Novago Therapeutics is a Swiss clinical-stage company specializing in developing treatments for acute spinal cord injury and diabetic retinopathy. As a spin-off from the University of Zürich, we are currently in our Series A funding round, supported by investors such as Pureos Bioventures, Neurimmune, and non-dilutive funding sources.
We are advancing two key assets: Spinal Cord Injury (NG004) and Diabetic Retinopathy (NG050).
May 6, 15:15 - 15:30, room Montreal
Novigenix is a precision medicine Tech Bio offering state-of-the-art ImmunoTranscriptomic liquid biopsy solutions with unprecedented predictive capabilities for precision development of novel therapeutics. Our AI-enabled ISO-13485 certified RNA analytic platform delivers ImmunoPD biomarkers, insights into mechanism of action and resistance, and early markers for severe toxicity to accelerate clinical development.
May 6, 12:30 - 12:45, room Marriott 1+2
NXI Therapeutics creates tomorrow's disruptive immunotherapies that maintain immunocompetence. The company has identified 3rd generation isoform-specific BET inhibitors that provide a potent, autoimmune-selective immunomodulation. This unique profile may truly unlock the potential of epigenetic BET inhibition for the treatment of autoimmune and inflammatory diseases. The company focuses on clinical applications in T cell-mediated autoimmune skin conditions.
May 5, 14:45 - 15:00, room Singapore
Parexel is among the world’s largest CROs, providing full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, we collaborate with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials for patients.
May 6, 12:45 - 13:00, room Osaka/Samarkand
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks.
May 6, 16:30 - 16:45, room Montreal
ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From research through product commercialization, we provide the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as gene and cell therapy platforms including NBE, AAV, mRNA and LV development candidates. Our services comprise extended characterization as well as release and stability testing.
May 6, 15:00 - 15:15, room Osaka/Samarkand
PSI CRO is a global Swiss-based full-service contract research organization (CRO), the only Swiss CRO organically grown since 1995 to operate globally across 56 countries with 3,000 full-time staff (as of December 2024).
PSI specializes in the set-up and management of global pivotal registrational clinical trials and is known for its unfailing commitment to timely delivery.
May 5, 15:15 - 15:30, room Osaka/Samarkand
Pureos Bioventures is a venture capital fund to exclusively invest in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats.
May 5, 14:30 - 14:45, room Singapore
Clinical Stage Biotech – disrupting the $50bn cancer immunotherapy PD-1/PD-L1 market. Lead asset code-named Kinisoquin™ in Phase 3 Trial under FDA SPA. Targets PD-L1, VEGF, PDI TF, TMEM176 in Cancer, Thrombosis and Neurology. Potentially Best-in-Class Oral Therapeutic in the PD-1/PDL1 market with safety and efficacy advantages over PD-1 VEGF bispecific antibodies. Scientific Advisory Board consists of Global A-Team in Hematology Oncology and Neurology.
May 6, 16:00 - 16:15, room Montreal
RDP Pharma AG is a privately held biotech and seed investor based in Romanshorn, Switzerland. Our core team has a highly successful, proven track record of bringing new medications to the market, particularly in the field of oncology. We identify new therapeutic modalities to create breakthrough medicines, specifically through our rationally designed, targeted protein degradation platform PROMPTDegrader (PRoteasomal Oral Monovalent Protein Targeting).
May 6, 13:15 - 13:30, room Montreal
Release Therapeutics is a privately-held company developing the first cell macroencapsulated cell platform technology designed to deliver potent therapeutic proteins beyond the human blood-brain barrier. The company’s lead program is in preclinical development for the treatment of Metachromatic Leukodystrophy (MLD), a rare genetic disorder that leads to progressive loss of myelin and typically affects young children.
May 6, 16:15 - 16:30, room Singapore
Salvina Therapeutics is developing antibodies with a novel approach for targeting TNF and TNF superfamily members with the aim of improving their safety and efficacy, and facilitating the generation of novel bispecific therapies.
May 5, 15:00 - 15:15, room Singapore
Simplifying Progress
Sartorius is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions with a broad product portfolio, we help our customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably.
Meet our experts:
- in the panel discussion on May 5, 14:30, Room 1+2 Marriott Hotel
- in the presentation on May 6, 15:30 - 15:45, Room: Osaka/Samarkand
- at our booth 101
May 6, 15:30 - 15:45, room Osaka/Samarkand
SEAL Therapeutics develops an innovative gene therapy approach that overcomes the functional defects causing LAMA2-related muscular dystrophy. The approach involves AAV-based delivery of specifically designed artificial linker proteins to compensate for the missing laminin-alpha 2 in muscle fibers.
May 6, 15:30 - 15:45, room Singapore
DINAMIQS enhances gene therapy efficacy and safety with Swiss-quality manufacturing and seamless scalability. Our science-driven platform delivers optimized yields, in-house analytics, and personalized support, backed by Siegfried's century of pharmaceutical expertise. Trusted by biotech and pharma, we transform genetic medicine into success stories.
May 6, 15:15 - 15:30, room Osaka/Samarkand
Skyepharma is a leading CDMO specializing in innovative drug delivery and bioproduction solutions. Based in France, it offers end-to-end services, from formulation development to commercial manufacturing. Its proprietary Skyehub-Bioproduction® model provides biotech companies with fully equipped GMP facilities and expert resources. With expertise in modified-release formulations, complex generics, and highly potent compounds, Skyepharma delivers customized solutions.
May 6, 16:00 - 16:15, room Osaka/Samarkand
STALICLA SA is a Swiss clinical-stage biotech developing precision treatments for neurodevelopmental and neuropsychiatric disorders. Its lead assets, STP1 and a second NDD compound, are entering Phase 2 trials. STP7 (Mavoglurant) is progressing to Phase 3 with full US government funding. STALICLA is currently raising a $60M Series C to support Phase 2 development.
May 6, 15:30 - 15:45, room Montreal
Stromal Therapeutics AG is a Swiss biotech company developing novel therapies targeting stromal cells, with a primary focus on cardiovascular diseases. Our lead antibody, STx_001, has been successfully humanized and has demonstrated in vivo efficacy in models of acute myocarditis.Preclinical safety data support IND preparation, with a First-in-Human trial planned for 2026. The company is currently seeking Series A financing to advance clinical development.
May 5, 15:30 - 15:45, room Singapore
TANDEM Tx is pioneering a mechano-targeted therapeutic platform designed to selectively target the extracellular matrix in fibrotic diseases. TANDEM’s peptide drug conjugates target mechanical changes in fibrotic niche, to home-in with precision while minimising off-target effects. This breakthrough approach can potentially transform fibrosis treatment across multiple organs. Our lead program is focused on progressive pulmonary fibrosis, a fatal disease with no cure.
May 5, 15:15 - 15:30, room Singapore
TFS HealthScience is a global contract research organization that partners with biotechnology and pharmaceutical companies throughout their entire clinical development journey. With industry-leading expertise in key therapeutic areas and demand-driven strategic resourcing, TFS can meet the needs of our partners and sponsors. Our experts are passionate about their disciplines, continually learning, enhancing and dedicating themselves to the success of your trial.
May 5, 17:45 - 18:00, room Osaka/Samarkand
VACCENTIS is a European biotech based in Switzerland developing the next generation oncology therapy – individualized protein-based tumour vaccines.
May 6, 13:30 - 13:45, room Montreal
Vaderis is a clinical stage biotech based in Basel, specialising in rare diseases associated with vascular malformations. Vaderis's lead compound, known as VAD044, is a novel allosteric AKT-inhibitor which has Fast-Track designation granted by FDA. VAD044 is used for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT), an Orphan disease for which there are no approved therapies. VAD044 enters Phase 3 trials in 2025 and is years ahead of all HHT competitors.
May 6, 15:00 - 15:15, room Montreal
ValGenesis delivers integrated and smart solutions that support the digital transformation of the life sciences industry. With a portfolio that covers the whole product lifecycle, ValGenesis has a digital or technical solution that brings value to each step of your validation and manufacturing processes and their related activities.
May 6, 13:45 - 14:0, room Osaka/Samarkand
Versameb AG is a clinical-stage biotechnology company pioneering RNA-based therapeutics to address unmet medical needs. Its proprietary VERSagile platform optimizes RNA functionality for enhanced therapeutic potential. Lead candidate VMB-100, a novel mRNA therapy for stress urinary incontinence (SUI), is advancing to Phase 2a trials in 2025. Based in Basel, Versameb is committed to transforming medicine through innovative RNA science.
May 5, 15:00 - 15:15, room Montreal
Unlock the full potential of your injectable product!
Backed by 45 years of global experience, our technical, scientific, and operational expertise has made us a trusted CDMO partner for parenteral drug owners worldwide.
Discover how we keep injectable products on the path to success.
Get in touch regarding:
- Drug product development
- Clinical Manufacturing
- Analytical services
- Regulatory support
May 6, 13:00 - 13:15, room Osaka/Samarkand
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. We are working on advancing antibody-based therapies that enhance the immune system’s ability to combat these potentially life-threatening diseases. Since 2025, Humabs BioMed AG (acquired by Vir Biotechnology in 2017) and Vir Biotechnology operate with a unified brand.
May 5, 15:30 - 15:45, room Montreal
